Remix Therapeutics Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer
Get ready for the Roche (Remix), a $30M small molecule deal
WATERTOWN, Mass., Dec. 11, 2023 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that the Company will be participating in the 6th Annual RNA-Targeted Drug Discovery & Development Summit taking place December 12-14, 2023 in Boston, MA.
CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying...
RNA-focused Remix Therapeutics has wrapped up a $70 million series B, bringing its total fundraising haul north of $150 million even as precise pipeline details remain unknown.
CAMBRIDGE, Mass., March 24, 2022 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.
Remix Therapeutics—and its RNA reprogramming technology designed to produce small-molecule therapies—has caught the attention of J&J's Janssen Pharmaceuticals, with the two agreeing to a licensing deal that could exceed $1 billion.